TROG Cancer Research
Members Login   CQMS Login

Become a TROG member

Do you have a professional interest in radiotherapy research?

Join the Trans Tasman Radiation Oncology Group (TROG Cancer Research)

Half of all people diagnosed with cancer would benefit from radiotherapy. The Trans Tasman Radiation Oncology Group (TROG Cancer Research) is the peak Australasian body for research into this safe and effective treatment. TROG is currently the highest recruiting collaborative trials group in Australia.

Become a member - it's FREE!

Become part of our network of more than 1,400 professionals in this exciting field.

Affiliate membership is FREE and open to anyone qualified or training in a radiotherapy-related discipline.

By joining, you’ll help advance clinical research into a treatment that benefits many cancers including breast, skin, lung, prostate and bladder, gynaecological, and head and neck.

  • Network with like-minded professionals
  • Stay up-to-date with industry news and trial updates in our monthly eNews
  • Access trial resources and Quality Assurance resources
  • Utilise the knowledge of TROG’s specialised committees

Or become a full member

Anyone fully qualified in their discipline, including radiation oncologists, medical oncologists, radiation therapists, medical physicists, statisticians, data managers, nurses and surgeons, can become a full TROG member.

For just $180+gst per year, full members hold voting rights at TROG meetings; can submit proposals for new trials; or become a Board member or Trial Chair.

  • Receive support at all stages of your trial’s development
  • Strengthen your grant application by aligning with TROG
  • Hold voting rights on trial protocols and other policies
  • Ensure treatment is safely administered via our QA program

All TROG members have access to the information in the members' section of the website, which includes the TROG Member Forum, Member directory and Member messenger; minutes and presenations from TROG meetings, copies of trial protocols and the TROG Policy and Procedures Manual .

> Download TROG Membership Benefits poster

Register now

Applications for membership require a personal recommendation by two full members (a Proposer and a Seconder). Once you have identified two full members who will nominate you for membership, the application process simply involves choosing the nominating members from the list of Full Members in the online registration form (click on Register Now button below). The nominating members will by contacted by TROG Central Operations to confirm their support for your membership application.

Member guarantee

TROG is a company limited by guarantee under the Corporations Act. The liability of members is limited to payment of a nominal guarantee of A$10 in the event that the company is wound up. If required, this contribution would support payment of the debts and liabilities of the company, including the costs of the winding up.  By subscribing as a full member of TROG you undertake to provide this guarantee in the amount of A$10, if required. This undertaking continues for one year after a member ceases to be a member of the company.

 

TROG conducts world-class research in radiotherapy-based clinical trials.


Latest News

  • 12 Feb 2019

    a new clinical trial by trog cancer research has shown for the first time that a new radiotherapy technique produced greater survival rates in early stage inoperable lung cancer patients, compared to conventional radiation treatment. the trog 09.02 chisel study aimed to investigate if...

  • 29 Jan 2019

    results from australia’s and new zealand’s biggest cancer trial have identified the best treatment regime for men suffering from newly-diagnosed aggressive but localised prostate cancer. the radar study, run through trog cancer research, compared the use of hormone treatment (longer v...

  • 07 Aug 2018

    trog cancer research has been successful in being awarded a $1.5 million grant (2018-2020) under the cancer australia support for cancer clinical trials program. the funding from cancer australia provides essential infrastructure for trog to build our capacity to undertake cancer...

  • 07 Aug 2018

    the board of trog cancer research is pleased to announce the appointment of susan goode as the new trog chief executive officer. susan is formerly the centre manager for the hunter cancer research alliance at the university of newcastle. in this role, she was key player in a strate...

  • 16 May 2018

    the inaugural trog trek has raised more than $10,000 for trog's cancer clinical trials. the group of volunteers took on a five-day 50 kilometre trek in the spectacular bay of fires region in north east tasmania in march. each of the team members either held fundraising events or...

  • 16 May 2018

    p style="font-variant-ligatures: normal;font-variant-caps: normal;orphans: 2; text-align:start;widows: 2;-webkit-text-stroke-width: 0px;text-decoration-style: initial; text-decoration-color: initial;word-spacing:0px">span style="font-size:11.0pt; font-family:">trog board presid...

  • 16 May 2018

    more than 270 people attended the trog 2018 annual scientific meeting (asm) in hobart, tasmania from 19-22 march. the asm was the 30th for trog and attendees included oncologists, radiation therapists, physicists, study coordinators and data managers. delegates heard from a host of...

  • 27 Feb 2018

    trog stalwart professor bryan burmeister is retiring from his position at princess alexandra hospital (pah) in brisbane. the highly respected radiation oncologist has worked in various positions with queensland health for 29 years. he has been at pah for the past 16 years. profe...

  • 06 Feb 2018

    with every millimetre counting in radiation therapy treatment, a new world first study developed in australia could eventually benefit cancer patients across the world. a new trog study called 'liver ablative radiotherapy with kim' or td 17.03 lark has received $583,000 from the ca...

  • 06 Feb 2018

    a new study investigating the use of cutting-edge stereotactic ablative _ radiotherapy (sabr) to treat patients with inoperable kidney cancer has been received $589,000 in funding from cancer australia. trog researcher, a/prof shankar siva, from the university of melbourne and the ...